Advances in male contraception

Bibliography

• UNITED NATIONS: World contraceptiveuse 1994. In: UN Department for Economic and Social Information and Policy Analysis, Population Division (ST/ESA/SER.A/143), New York, USA (1994).
   Google Scholar
• MCCULLAGH EP, MCGURL FJ: Further observations on the clinical use of testosterone propionate. J. Urol. (1939) 42:1265–1267.
   Google Scholar
• WAITES GEH, WANG C, GRIFFIN PD: Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int. J. Androl. (1998) 21:8–12.
   PubMed Web of Science ®Google Scholar
• REND, NAVARRO B, PEREZ G et al.: A sperm ion channel required for sperm motility and male fertility. Nature (2001) 413:603–609.
   PubMed Web of Science ®Google Scholar
• AKAMA T, NAKAGAWA H, SUGIHARA K et al: Germ cell survival through carbohydrate-mediated interaction with Sertoli cells. Science (2002) 295:124–127.
   PubMed Web of Science ®Google Scholar
• SHARPE RM: Regulation of spermatogenesis. In: The physiology of reproduction. E Knobil, JD Neill (Eds.) 2nd edition. Raven Press, New York, USA (1994):3823–3831.
   Google Scholar
• MORSE HC, HORIKE N, ROWLEY MJ, HELLER CG: Testosterone concentrations in testes of normal men: effects of testosterone propionate administration. J. Clin. Endocrinol. Metab. (1973) 37:882–888.
   Google Scholar
• BARFIELD A, MELO J, COUTINHO E etal.: Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception (1979) 20:121–127.
   Google Scholar
• SWERDLOFF RS, CAMPFIELD LA, PALACIOS A, MCCLURE RD: Suppression of human spermatogenesis by depot androgen: potential for male contraception. J. Steroid Biochern (1979) 11:663–670.
   PubMed Web of Science ®Google Scholar
• STEINBERGER E, SMITH KD: Testosterone enanthate, a possible reversible male contraceptive. Contraception (1977) 16:261–268.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANISATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet (1990) 336:955–959.
   PubMed Web of Science ®Google Scholar
• ••First study examining the efficacy oftestosterone as a contraceptive in azoospermic men.
   Google Scholar
• WORLD HEALTH ORGANISATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Feral. Sterd. (1996) 65:821–829.
   PubMed Web of Science ®Google Scholar
• ••First study also investigating efficacy oftestosterone as a contraceptive in oligozoospermic men.
   Google Scholar
• ANDERSON RA, WALLACE EM, WU FCW: Effect of testosterone enanthate on serum lipoproteins in man. Contraception (1995) 52:115–119.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, KNOPP RH, RIVIER JE,BREMNER WJ: Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. Clin. Endocrinol. Metab. (1994) 78:855–861.
   Google Scholar
• MERIGGIOLA MC, MARCOVINA S, PAULSON CA, BREMNER WJ: Testosterone enanthate at the dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int. J. Andra (1995) 18:237–242.
   PubMed Web of Science ®Google Scholar
• WU FCW, FARLEY TMM, PEREGOUDOV A, WAITES GMH, WHO TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Steril. (1996) 65:626–636.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANISATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. hat. J. Andra (1995) 18:157–165.
   Web of Science ®Google Scholar
• HANDELSMAN DJ, FARLEY TMM, PEREGOUDOV A, WAITES GMH, WHO TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertid. Sten7. (1995) 63:125–133.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, WALLACE AM, WU FCW: Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study III. Higher 5a-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J. Clin. Endocrinol. Metab. (1996) 81:902–908.
   Web of Science ®Google Scholar
• •Study finding increased 5a-reductase activity in men who remain oligizoospermic compared to those who are azoospermic with TE treatment.
   Google Scholar
• FRICK J, BARTSCH G, WEISKE WH: The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose. Contraception (1977) 15:669–677.
   PubMed Web of Science ®Google Scholar
• FRICK J, BARTSCH G, WEISKE WH: The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels. Contraception (1977) 15:649–668.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-SANCHEZ F, FAUNDES A, BRACHE V, LEON P: Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate. Contraception (1977) 15:635–648.
   PubMed Web of Science ®Google Scholar
• BRENNER PF, MISHELL DR, BERNSTEIN GS, ORTIZ A: Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive. Contraception (1977) 15:679–691.
   PubMed Web of Science ®Google Scholar
• MELO JF, COUTINHO EM: Inhibition ofspermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate. Contraception (1977) 15:627–635.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANISATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil. Steil]. (1993) 60:1062–1068.
   PubMed Web of Science ®Google Scholar
• •Demonstrates increased suppression among Asian men with an androgen-progestogen combination.
   Google Scholar
• FAUNDES A, BRACHE V, LEON P, SCHMIDT F, ALVAREZ-SANCHEZ F: Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg). hit. J. Andra (1981) 4:235–245.
   Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, HOWE CJ, TURNER L, MACKEY M-A: Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J. Clin. Endocrinol. Metab. (1996) 81:4113–4121.
   PubMed Web of Science ®Google Scholar
• FOEGH M, NICHOL M, LETERSON IB, SCHOU G: Clinical evaluation of long-term treatment with levonorgestrel and testosterone enanthate in normal men. Contraception (1980) 21:631–640.
   PubMed Web of Science ®Google Scholar
• BEBB RA, ANAWALT BD, CHRISTENSEN RB, PAULSEN CA, BREMNER WJ, MATSUMOTO AM: Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J. Clin. Endocrinol. Metab. (1996) 81:757–762.
   PubMed Web of Science ®Google Scholar
• •Clear demonstration of additive effect of progestogens.
   Google Scholar
• ANAWALT BD, BEBB RA, BREMNER WJ, MATSUMOTO AM: A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. Andra (1999) 20:407–414.
   PubMed Web of Science ®Google Scholar
• FOTHERBY K, YONG-EN S, HOWARD G, ELDER MG, MUGGERIDGE J: Return of ovulation and fertility in women using norethisterone oenanthate. Contraception (1984) 29:447–455.
   PubMed Web of Science ®Google Scholar
• KAMISCHKE A, VENHERM S, PLOGER D, VON ECKARDSTEIN S, NIESCHLAG E: Intramuscular testosterone undecanoate with norethisterone enanthate in a clinical trial for male contraception. J. Clin. Endocrinol Metab. (2001) 86:303–309.
   PubMed Web of Science ®Google Scholar
• •Demonstrates high efficacy with androgen-progestogen combination with convenient equal injection periods for both steroids.
   Google Scholar
• OJOS00 T, RAYNAUD JP: Receptor binding profiles of progestins. In: Steroids and endometrial cancer. C Flamingi (Ed.) Raven Press, New York, USA (1983):11–28.
   Google Scholar
• LEMUS AE, ENRIQUEZ J, GARCIA GA, GRILLASCA I, PEREZ-PALACIOS G: 5-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency.' Steroid. Biochem. MM. Biol. (1997) 60:121–129.
   PubMed Web of Science ®Google Scholar
• WU FCW, BALASUBRAMANIAN R, MULDERS TMT, COELINGH-BENNINK HJT: Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. Clin. Endocrinol Metab. (1999) 84:112–122.
   Google Scholar
• •Demonstrates relative contributions of androgen and progestogens in a combined regime and their narrow dose-response relationship with regards to efficacy.
   Google Scholar
• ANAWALT BD, HERBST KL, MATSUMOTO AM, MULDERS TM, COELINGH-BENNINK HJ, BREMNER WJ: Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil. Steril (2000) 74:707–714.
   PubMed Web of Science ®Google Scholar
• MARTIN CW, RILEY SC, EVERINGTON D et al.: Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. Hum. Reprod. (2000) 15: 1515–1524.
   PubMed Web of Science ®Google Scholar
• KINNIBURGH D, ANDERSON RA, CHENG L, ZHOU H, BAIRD DT: Contraceptive potential of oral desogestrel with depot testosterone in men. Intl. J. Obstet. Cynaecol (2000) 70:FC1.22.05.
   Google Scholar
• GAO E, LIN C, GUI Y, LI L, HE C: Inhibiting effects of Sino-implant plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. Reprod. Contraception (1999) 10:98–105.
   PubMedGoogle Scholar
• ANDERSON RA, KINNIBURGH D, BAIRD DT: Etonogestrel implants with depot testosterone: dose-dependent suppression of spermatogenesis for long- acting male contraception. Ear: Contracept. Reprod. Health Care (2002) In press.
   Google Scholar
• WANG C, YEUNG RTT: Use of low-dosage cyproterone acetate as a male contraceptive. Contraception (1980) 21:245–269.
   PubMed Web of Science ®Google Scholar
• ROY: Experience in the development of hormonal contraception in the male. In: Recent advances M human reproduction. RH A (Ed.). Fondazione per gli Studi sulla Reproduzione Umana, Rome, Italy (1985):95–104.
   Google Scholar
• MERIGGIOLA MC, BREMNER WJ, PAULSEN CA et al: A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J. Clin. Endocrinol Metab. (1996) 81:3018–3023.
   PubMed Web of Science ®Google Scholar
• •Illustrates the adjuvant benefit of including an anti-androgen in male contraceptive regimes.
   Google Scholar
• MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, DI CINTIO G, FLAMIGNI C: Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum. Reprod. (1998) 13:1225–1229.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, PAVANI A, CAPELLI M, FLAMINGI C: An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil. Sterd. (1997) 68:844–850.
   PubMed Web of Science ®Google Scholar
• RUSSELL DW, WILSON JD: Steroid 5 alpha-reductase: two genes/two enzymes. Annu. Rev Biochem. (1994) 63:25–61.
   PubMed Web of Science ®Google Scholar
• PAYNE AH, KAWANO A, JAFFE RB: Formation of dihydrotestosterone and other 5a-reduced metabolites by isolated seminiferous tubules and suspension of interstitial cells in a human testis.," Clin. Endocrinol Metab. (1973) 37:448–453.
   Google Scholar
• RIVAROLA MA, PODESTA EJ, CHEMES HE, AGUILAR D: In vitro metabolism of testosterone by whole human testis, isolated seminiferous tubules and interstitial tissue. Clin. Endocrinol Metab. (1973) 37:454–460.
   Google Scholar
• THIGPEN AE, SILVER RI, GUILEYARDO JM, CASEY ML, MCCONNELL JD, RUSSELL DW: Tissue distribution and ontogeny of steroid 5a-reductase isoenzyme expression. Clin. Invest. (1993) 92:903–910.
   Google Scholar
• O'DONNELL L, STANTONP, WREFORD NG, ROBERTSON DM, MCLACHLAN RI: Inhibition of 5a-reductase activity impairs the testosterone-dependent restoration of spermiogenesis in adult rats. Endocrinology (1996) 137:2703–2710.
   PubMed Web of Science ®Google Scholar
• LOOKINGBILL DP, DEMERS LM, WANG C, LEUNG A, RITTMASTER RS, SANTEN RJ: Clinical and biochemical parameters of androgen action in normal healthy caucasian versus Chinese subjects. Clin. Endocrinol Metab. (1991) 72:1242–1248.
   Google Scholar
• ROSS RK, BERNSTEIN L, LOBO RA et al.: 5-alpha-reductase activity and the risk of prostatic cancer among Japanese and US white and black males. Lancet (1992) 339:887–889.
   PubMed Web of Science ®Google Scholar
• KINNIBURGH D, ANDERSON RA, BAIRD DT: Suppression of spermatogenesis with desogestrel and testosterone pellets in not enhanced by addition of finasteride. Andra (2001) 22:88–95.
   PubMed Web of Science ®Google Scholar
• MCLACHLAN RI, MCDONALD J, RUSHFORD D, ROBERTSON DM, GARRETT C, BAKER HWG: Efficacy and acceptability of testosterone implants, alone or in combination with a 5a-reductase inhibitor, for male contraception. Contraception (2000) 62:73–78.
   PubMed Web of Science ®Google Scholar
• LUBAHN DB, JOSEPH DR, SULLIVAN PM, WILLARD HF, FRENCH FS, WILSON EM: Cloning of human androgen receptor complementary DNA and localization of the X-chromasome. Science (1988) 240:327–330.
   PubMed Web of Science ®Google Scholar
• HESS RA, BUNICK D, LEE KH et al: A role for oestrogens in the male reproductive system. Nature (1997) 390:509–512.
   PubMed Web of Science ®Google Scholar
• KORACH KS, COUSE JF, CURTIS SW et al.: Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Frog. Holm. Res. (1996) 51:159-186; discussion 186–158.
   Google Scholar
• SMITH EP, BOYD J, FRANK GR et al: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl. Med. (1994) 331:1056–1061.
   PubMed Web of Science ®Google Scholar
• MORISHIMA A, GRUMBACH MM, SIMPSON ER, FISHER C, QIN K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Clin. Endocrinol Metab. (1995) 80:3689–3698.
   Google Scholar
• CARANI C, QIN K, SIMONI M et al.: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl. I Med. (1997) 337:91–95.
   PubMed Web of Science ®Google Scholar
• HAYES FJ, SEMINARA SB, DECRUZ S, BOEPPLE PA, CROWLEY WF, JR.: Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. Clin. Endocrinol Metab. (2000) 85:3027–3035.
   Google Scholar
• EWING LL, DESJARDINS C, IRBY DC,ROBAIRE B: Synergistic interaction of testosterone and oestradiol inhibits spermatogenesis in rats. Nature (1977) 269:409–411.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, WISHART S, CONWAY AJ: Oestradiol enhances testosterone-induced suppression of human spermatogenesis. Hum. Reprod. (2000) 15:672–679.
   PubMed Web of Science ®Google Scholar
• CUMMINGS DE, BREMNER WJ: Prospects for new hormonal male contraceptives. Endocrinol and Metabol Clinics of North America (1994) 22:893–922.
   Google Scholar
• PAVLOU SN, INTERLANDI JW, WAKEFIELD G, RIVIERJ, VALE W, RABIN D: Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone. Andra (1986) 7:228–233.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, NASHAN D, HUBERT W, NIESCHLAG E: Depot gonadotrophin- releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. I Clin. Endocrinol Metab. (1992) 74:84–90.
   PubMed Web of Science ®Google Scholar
• PAVLOU SN, INTERLANDI JW, WAKEFIELD G et al.: Gonadotropins and testosterone escape from suppression during prolonged luteinizing hormone-releasing hormone antagonist administration in normal men. J. Clin. Endocrinol Metab. (1987) 64:1070–1074.
   PubMed Web of Science ®Google Scholar
• TOM L, BHASIN S, SALAMEH W et al.: Induction of azoospermia in normal men with combined Nal-Glu gonadotrophin releasing hormone antagonist and testosterone enanthate. Clin. Endocrinol Metab. (1992) 75:476–483.
   Google Scholar
• BAGATELL CJ, MATSUMOTO AM, CHRISTENSEN RB, RIVIERJE, BREMNER WJ: Comparison of a gonadotrophin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. Clin. Endocrinol Metab. (1993) 77:427–432.
   Google Scholar
• BEHRE HM, KLEISCH S, LEMCKE B, NIESCHLAG E: Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by 19-nortestosterone alone. Proc 77th Annual Meeting of the Endocrine Society Washington DC, USA (1995).
   Google Scholar
• SWERDLOFF RS, BAGATELL CJ, WANG C et al.: Suppression of spermatogenesis in man induced by Nal-Glu gonadotrophin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.' Clin. Endocrinol Metab. (1998) 83:3527–3533.
   Google Scholar
• ••Interesting study introducing a biphasicapproach to male contraception using a GnRH antagonist - induction and maintenance.
   Google Scholar
• CHO N, HARADA M, IMAEDA T et al.: Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. I Med. Chem. (1998) 41:4190–4195.
   PubMed Web of Science ®Google Scholar
• SCHOMEYER T, WICKINGS EJ, FREISCHEM CW, NIESCHLAG E: Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol (1983) 102:456–462.
   PubMedGoogle Scholar
• MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, VALDISERRI A, FLAMIGNI C: "A male pill": preliminary studies of oral testosterone undecanoate (TU) and cyproterone acetate (CPA) to suppress spermatogenesis in normal men. 10th International Congress of Endocrinology (1996):P2–595.
   Google Scholar
• BEHRE HM, NIESCHLAG E: Testosterone buciclate (20-Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester." Clin. Endocrinol Metab. (1992) 75:1204–1210.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, OBERPENNING F, NIESCHLAG E: Comparative pharmacokinetics of androgen preparations: Application of computer analysis and simulation. In: Testosterone: action, deficiency substitution. E Nieschlag, HM Behre (Eds.) Springer-Verlag, Berlin, Germany (1990):115–135.
   Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Suppression of human spermatogenesis by testosterone implants. Clin. Endocrinol Metab. (1992) 75:1326–1332.
   Google Scholar
• •Illustrates dose-sparing effect of using testosterone implants in comparison to TE, avoiding supraphysiological levels with similar efficacy.
   Google Scholar
• BEHRE HM, BAUS S, KLEISCH S, KECK C, SIMONI M, NIESCHLAG E: Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. Clin. Endocrinol Metab. (1995) 80:2394–2403.
   Google Scholar
• ZHANG GY, GU YQ, WANG XH, CUI YG, BREMNER WJ: A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.' Andra (1998) 19:761–768.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, BOCHTER D, VON ECKARDSTEIN S, ABSHAGEN K, SIMONI M, BEHRE HM: Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin. Endocrinol (1999) 51:757–763.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, ABSHAGEN K, OETTEL M, HOBLER D, NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur: Endocrinol (1999) 140:414–419.
   PubMed Web of Science ®Google Scholar
• ZHANG G-Y, GUY-Q,WANG X-H, CUI Y-G, BREMNER WJ: A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. I Clin. Endocrinol Metab. (1999) 84:3642–3647.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Pharmacokinetics and pharmacodynamics of testosterone pellets in man. I Clin. Endocrinol Metab. (1990) 71:216–222.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ: Androgen delivery systems: testosterone pellet implants. In: Pharmacology biology, and clinical applications of androgens: current status and future prospects. S Bhasin, HL Gabelnick, JM Speiler, RS Swerdloff, C Wang, C Kelly (Eds.) Wiley-Liss, New York, USA (1996):459–469.
   Google Scholar
• ANDERSON RA, KINNIBURGH D, BAIRD DT: Oral desogestrel with depot testosterone results in consistent suppression of spermatogenesis in caucasian men. Proceeding of the 11th International Congress of Endocrinology Sydney, Australia (2000).
   Google Scholar
• PLACE VE AL, PRATHER DA, TRUNNEL N, YATES FE: Transdermal testosterone replacement through genital skin. In: Testosterone: action, deficiency substitution. EBH Neischlag (Ed.). Springer-Verlag, Berlin, Germany (1990):165–182.
   Google Scholar
• MEIKLE AW, MAZER NA, MOELLMER JF et al.: Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men." Clin. Endocrinol Metab. (1992) 74:623–628.
   Google Scholar
• PARKER S, ARMITAGE M: Experience with transdermal testosterone replacement therapy for hypogonadal men. Clio. Endocrinol. (ux!) (1999) 50:57–62.
   PubMed Web of Science ®Google Scholar
• DOBS AS, MEIKLE AW, ARVER S, SANDERS SW, CARAMELLI KE, MAZER NA: Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Clio. Endocrinol. Metab. (1999) 84:3469-3478. so.BENNETT NJ: A burn-like lesion caused by a testosterone transdermal system. Burns (1998) 24:478–480.
   Google Scholar
• WANG C, IRANMANESH A, BERMAN N et al.: Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study. J. Clio. Endocrinol. Metab. (1998) 83:2749–2757.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF RS, WANG C: Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. BailBeres Clio. Endocrinol. Metab. (1998) 12:501–5061.
   PubMed Web of Science ®Google Scholar
• LY LP, JIMENEZ M, ZHUANG TN, CELERMAJER DS, CONWAY AJ, HANDELSMAN DJ: A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. Clio. Endocrinol. Metab. (2001) 86:4078–4088.
   PubMed Web of Science ®Google Scholar
• WANG C, SWERDLOFF RS, IRANMANESH A et al.: Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clio. Endocrinol. (Ox!) (2001) 54:739–750.
   PubMed Web of Science ®Google Scholar
• SOUFIR J-C, JOUANNET P, MARSON J,SOUMAH A: Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Acta Endocrinol. (1983) 102:625–632.
   PubMedGoogle Scholar
• HAIR WM, KITTERIDGE K, O'CONNOR DB, WU FC: A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. I Clio. Endocrinol. Metab. (2001) 86:5201–5209.
   PubMed Web of Science ®Google Scholar
• BOCHTER D, VON ECKARDSTEIN S, VON ECKARDSTEIN A et at Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. Clio. Endocrinol. Metab. (1999) 84:1244–1249.
   PubMed Web of Science ®Google Scholar
• KUMAR N, DIDOLKAR AK, MONDER C, BARDIN CW, SUNDARAM K: The biological activity of 7a-methy1-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology (1992) 130:3677–3683.
   PubMed Web of Science ®Google Scholar
• LAMORTE A, KUMAR N, BARDIN CW, SUNDARAM K: Aromatization of 7 alpha-methy1-19-nortestosterone by human placental microsomes M vitro. Steroid Biochem. Mol. Biol. (1994) 48:297-304. loo. CUMMINGS DE, KUMAR N, BARDIN CW, SUNDARAM K, BREMNER WJ: Prostate-sparing effects in primates of the potent androgen 7a-methy1-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J. Clio. Endocrinol. Metab. (1998) 83:4212–4219.
   Google Scholar
• •Evidence in primates for prostate-sparing advantage of the synthetic androgen MENT.
   Google Scholar
• SUNDARAM K, KEIZER-ZUCKER A, THAU RB, BARDIN CW: Reversal of testicular function after prolonged suppression with an LHRH agonist in rhesus monkeys. Andra (1987) 8:103–107.
   PubMed Web of Science ®Google Scholar
• NOÈ G, SUVISAARI J, MARTIN C et al.: Gonadotrophin and testosterone suppression by 7a-methyl- 1 9-nortestosterone acetate administered by subdermal implant to healthy men. Hum. Reprod. (1999) 14:2200–2206.
   PubMed Web of Science ®Google Scholar
• •Demonstration of suppressive effect of a synthetic androgen on gonadotrophins.
   Google Scholar
• ANDERSON RA, MARTIN CW, KUNG AWC et al.: 7a-Methy1-19-Nortestosterone (MENT) maintains sexual behavior and mood in hypogonadal men. Clio. Endocrinol. Metab. (1999) 84:3556–3562.
   PubMed Web of Science ®Google Scholar
• MARTIN CW, ANDERSON RA, CHENG L et al.: Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum. Reprod. (2000) 15:637–645.
   PubMed Web of Science ®Google Scholar
• •Multi-centre study of men's attitudes to hormonal contraception, highlighting variability in attitude and emphasising increasing role of men in family planning.
   Google Scholar
• GLASIER A, ANAKWE R, EVERINGTON D et al.: Would women trust their partners to use a male pill? Hum. Reprod. (2000) 15:646–649.
   Web of Science ®Google Scholar
• •Multi-centre survey emphasising positive attitude of women towards male hormonal contraception. los. KUIPER GGJM, ENMARK E, PELTO-HUIKKO M, NILSSON S, GUSTAFSSON J-A: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Nati Acad. Si". USA (1996) 93:5925–5930.
   PubMed Web of Science ®Google Scholar
• EDWARDS JP, HIGUCHI RI, WINN DT et al.: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H- pyranoquinolin-2-one. Bioorg. Med.Chem. Lett. (1999) 9:1003–1008.
   PubMed Web of Science ®Google Scholar
• NEGRO-VILAR A: Selective androgen receptor modulators (SARMS): a novel approach to androgen therapy for the new millenium.j. Clio. Endocrinol. Metab. (1999) 84:3459-3462. los. EDWARDS JP, ZHI L, POOLEY CL et al: Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno [3,4-f ]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. Med. Chem. (1998) 41:2779–2785.
   Google Scholar
• ZHI L, TEGLEY CM, KALLEL EA et al: 5-Aryl-1, 2-dihydrochromeno [3,4-flquinolines: a novel class of nonsteroidal human progesterone receptor agonists. Med. Chem. (1998) 41:291–302.
   Web of Science ®Google Scholar
• ZHENGWEI Y, WREFORD NG, ROYCE P, DE KRETSER DM, MCLACHLAN RI: Stereological evaluation of human spermatogenesis after suppression by testosterone treatment: heterogeneous pattern of spermatogenic impairment. Clio. Endocrinol. Metab. (1998) 83:1284–1291.
   PubMed Web of Science ®Google Scholar
• SINHA HIKIM AP, WANG C, LEUNG A, SWERDLOFF RS: Involvement of apoptosis in the induction of germ cell degeneration in adult rats after gonadotrophin-relesing hormone antagonist treatment. Endocrinology (1995) 136:2770–2775.
   PubMed Web of Science ®Google Scholar
• O'DONNELL L, NARULA A, BALOURDOS G et al.: Impairment of spermatogonial development and spermiation after testosterone-induced gonadotropin suppression in adult monkeys (Macaca fascicularis)../ Clio. Endocrinol. Metab. (2001) 86:1814–1822.
   Google Scholar